Trinity Biotech

Trinity Biotech ROE

The Return on Equity (ROE) of Trinity Biotech (TRIB) as of Nov 11, 2026 is 51.92 %. In the previous year, Return on Equity (ROE) was 90.36 % — a change of -42.54% (lower).

ROE

51.92 %

YoY

-42.54%

Last updated:

In 2025, Trinity Biotech's return on equity (ROE) was 51.92 %, a -42.54% increase from the 90.36 % ROE in the previous year.

The Trinity Biotech ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
5.43 USD
Jan 1, 2019
-86.27 USD
Jan 1, 2020
287.88 USD
Jan 1, 2021
-274.29 USD
Jan 1, 2022
1,884.28 USD
Jan 1, 2023
100.29 USD
Jan 1, 2024
90.36 USD
Jan 1, 2025
51.92 USD
The Trinity Biotech ROE history
YEARROEYoY
51.92 %-42.54%
90.36 %-9.90%
100.29 %-94.68%
1,884.28 %-786.96%
-274.29 %-195.28%
287.88 %-433.69%
-86.27 %-1,690.22%
5.43 %-108.78%
-61.77 %-33.26%
-92.55 %-1,008.20%
10.19 %+16.61%
8.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding Trinity Biotech's Return on Equity (ROE)

Trinity Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Trinity Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Trinity Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Trinity Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Trinity Biotech stock

Return on Equity (ROE) of Trinity Biotech is 51.92 % in 2025.

Return on Equity (ROE) of Trinity Biotech changed from 90.36 % to 51.92 %, representing a -42.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trinity Biotech

All Key Metrics — Trinity Biotech